Re Pluenneke

Re Pluenneke

University of Kansas Medical Center - Kansas City / United States
Others
AD Scientific Index ID: 4602208
person_outline Re Pluenneke's MOST POPULAR ARTICLES
1-) Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I–III triple-negative breast cancer (NeoSTOP)P Sharma, BF Kimler, A O\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Dea, L Nye, YY Wang, R Yoder, JM Staley, ...Clinical Cancer Research 27 (4), 975-982, 2021542021
2-) Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group StudySG Urba, K Chansky, PJ VanVeldhuizen, RE Pluenneke, JK Benedetti, ...Investigational new drugs 22, 91-97, 2004542004
3-) Abstract S4-2: First efficacy results of a randomized, open-label, phase III study of adjuvant doxorubicin plus cyclophosphamide, followed by docetaxel with or without …J O\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\'Shaughnessy, D Paul, C Stokoe, J Pippen Jr, JL Blum, L Krekow, ...Cancer Research 70 (24_Supplement), S4-2-S4-2, 2010512010
4-) Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancerR Yoder, BF Kimler, JM Staley, K Schwensen, YY Wang, K Finke, A O’Dea, ...NPJ Breast Cancer 8 (1), 80, 2022322022
5-) Phase II trial of weekly docetaxel/gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancerJA O\'Shaughnessy, R Pluenneke, J Sternberg, P Khandelwal, D Ilegbodu, ...Clinical breast cancer 6 (6), 505-510, 2006232006